Patient satisfaction following a switch from treat-and- extend to observe-and-plan regimen in age-related macular degeneration [PDF]
, 2022 Objective Standard treatment of neovascular age-related macular degeneration (nAMD) is intravitreal injections (IVI) of antivascular endothelial growth factor (anti-VEGF) according to treat-and-extend (TnE). Observe-and-plan (OnP), a new regimen based on
Austeng, Dordi +3 more
core +1 more source
Clinical Ophthalmology, 2023 Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma ...
Miyakubo T +8 more
doaj
Ophthalmology and Therapy, 2019 Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou +3 more
doaj +1 more source
Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
Российский офтальмологический журнал, 2023 Purpose. To evaluate long-term results of anti-VEGF therapy performed in a modified “treat-and-extend” regimen in macular edema secondary to central retinal vein occlusion.Material and methods.
A. B. Galimova, V. U. Galimova
doaj +1 more source
Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]
, 2020 AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J +6 more
core
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited [PDF]
, 2017 BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of ...
Adam Turpcu +4 more
core +1 more source
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration [PDF]
, 2021 PURPOSE: Although intraocular anti-vascular endothelial growth factors (anti-VEGFs) are effective as treatment of neovascular age-related macular degeneration (nAMD), the (economic) burden on the healthcare system is considerable. A treat-and-extend (T&E)
de Jong, L. A. +5 more
core +1 more source
TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina, 2014 To evaluate the factors affecting visual and anatomical outcomes and the number of intravitreal bevacizumab injections required in the treatment of neovascular age-related macular degeneration using a treat-and-extend regimen.Retrospective consecutive case series.
Rush, R +4 more
openaire +2 more sources
Treatment of exudative age-related macular degeneration with intravitreal ranibizumab in clinical practice: a 3-year follow-up [PDF]
, 2013 PURPOSE: To evaluate the 36-month efficacy of intravitreal ranibizumab injections for choroidal neovascularization secondary to age-related macular degeneration (AMD) in real world clinical practice.
Faria de Abreu, JR +6 more
core +1 more source
Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. [PDF]
, 2014 AIMS: The purpose of this study was to clinically validate an individually planned treatment regimen for neovascular age-related macular degeneration (nAMD), termed, observe and plan.
Ambresin, A. +4 more
core +1 more source